GAME ON, page-9

I must commend Morgans Stockbroking. They were in early on Resapp.

today had an updated research note.

They put a 35c valuation on it, but apply a 75% discount to that based on their perceived potential for delays in recruitment.

Considering they have recruited their first patient in this trial earlier than in the first trial, and it is a record cold northern hemisphere winter, and the hospitals are more familiar with the trial, i think that discount is a bit overdone and should be reduced as they update the market on numbers over coming months.